ERBB2 and breast cancer: In another study that recruited locally recurrent or metastatic HER2+ breast cancer patients, the effectiveness and safety of pertuzumab and trastuzumab joined with a taxane (docetaxel, paclitaxel, or nab-paclitaxel) at investigator choice were the main endpoints.